Services → Pharmacogenomics

Pharmacogenomic analysis for the development of personalized medicine

Pharmacogenomic biomarker discovery and targeted method development, validation, and high-throughput analysis services

PHARMACOGENOMICS SERVICES

Pharmacogenomic biomarkers

Pharmacogenomic discovery

Genetic variations (e.g., SNPs, indels, CNVs, structural variants) that influence drug response, metabolism, efficacy, or toxicity are identified using next-generation sequencing (NGS) on the whole genome, coding regions, or targeted panels. Our optimized, automated workflows, from extraction to bioinformatics, enable pharmacogenomic screening for both small sample sets and large cohort analyses.

DNA-Seq

Pharmacogenetic testing

Precise, reproducible, and quantitative pharmacogenetic assays are essential for detecting SNPs, indels, CNVs, mutation analysis and structural variants. We design, optimize, and validate high-precision methods, such as qPCR and dPCR, to support small-scale studies and high-throughput clinical trial sample analysis.

qPCR

dPCR

GLP and GCLP compliant laboratory

We are accredited for Good Laboratory Practice (GLP) by the Swedish Board for Accreditation and Conformity Assessment (SWEDAC) for qPCR, dPCR, and molecular biology. In addition, we are Good Clinical Laboratory Practice (GCLP) compliant to ensure the safe and reliable analysis of clinical samples.

Pharmacogenomics at TATAA

Samples

Tissues
Blood
Liquid biopsies
Fresh frozen
FFPE
EDTA
PAXgene tubes

Analytes

Single nucleotide polymorphism (SNP)
Single nucleotide variants (SNVs)
Insertions and deletions (indels)
Copy number variations (CNVs)
Structural variants (SVs)
Cell free DNA (cfDNA)

What is pharmacogenomics?

Pharmacogenomics ensures that treatments are tailored to a patient’s genetic profile in personalized medicine, improving efficacy and minimizing adverse effects. Genetic variations affecting drug response can occur in drug-metabolizing enzymes, transporters, and receptors.

In advanced therapies, sequencing T-cell receptors (TCR) or B-cell receptors (BCR) could also be considered a pharmacogenomic approach, as it helps guide immune-targeted treatments.

Common pharmacogenomic biomarkers include single-nucleotide polymorphisms (SNPs), single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), structural variants (SVs), and cell-free DNA (cfDNA).

The difference between pharmacogenomics and pharmacogenetics?

Pharmacogenomics (PGx) and pharmacogenetics (PGt) are not the same. Pharmacogenomics studies how multiple genes or the entire genome influence drug response, while pharmacogenetics is a subfield of pharmacogenomics that focuses on how specific genetic variants in a single gene affect drug response. Pharmacogenetics typically examines single-gene mutations, such as those in metabolic enzyme genes.